Strikingly, we found that the sublocation of EZH2 staining was associated with lymph node metastasis in HER2-positive invasive BC tissues—82.6% (19/23) cases were positive for EZH2 expression in LN negative IDC specimens, as cytoplasm-located staining while 53.3% (8/15) cases were positive for EZH2 expression in LN positive IDC specimens as nucleus-located staining (Fig. 2C, p < 0.05). Here, EZH2 is linked to breast cancer.